ProfessorNicholas Mazarakis, FRSB
Chair MolBioMedicine and Head of Gene Therapy
Department of Brain Sciences - Faculty of Medicine
Orcid identifier0000-0001-9592-0157 (opens in a new tab)
- Chair MolBioMedicine and Head of Gene TherapyDepartment of Brain Sciences - Faculty of Medicine
- 020 7594 7024 (Work)
- E402, Burlington Danes, Hammersmith Campus, United Kingdom
BIO
Professor Nicholas D. Mazarakis holds the Lucas-Lee chair of Molecular BioMedicine and is head of Gene Therapy in the Department of Brain Sciences, Faculty of Medicine, Imperial College London. He is a molecular neuroscientist with an international reputation in gene therapy of neurological diseases. He has served as Vice President of Neurobiology at Oxford BioMedica plc, where he pioneered the first ever lentiviral gene therapy to the clinic for Parkinson’s disease (ProSavin®). His research focuses on investigating molecular pathways of neurodegeneration and developing translational gene therapies for neurological diseases. He received his Ph.D. from King’s College University of London and is an elected fellow of the Society of Biology. He has lectured in conferences worldwide and published in top science journals such as Nature, Science and PNAS. His research is supported by several grants including an Advanced Investigators award in 2008 and a Proof of Concept grant in 2013 from the European Research Council.
Videos:
Imperial College wins seven European Research Council Advanced Grants
Researching more focused gene therapies for motor neurone diseases:
Academic Health Sciences Centre (AHSC)
Imperial wins AHSC accreditation:
Videos:
Imperial College wins seven European Research Council Advanced Grants
Researching more focused gene therapies for motor neurone diseases:
Academic Health Sciences Centre (AHSC)
Imperial wins AHSC accreditation:
FACULTY
- Faculty of Medicine
POSITION NAME
- Chair MolBioMedicine and Head of Gene Therapy